▁British 8.59375
▁Bi 8.046875
ote 1.81640625
ch 0.12213134765625
▁pl 7.98828125
c 0.22021484375
' 5.0078125
s 0.0024871826171875
▁cancer 7.55078125
▁drug 1.05859375
▁Mar 8.2421875
im 6.8984375
ast 0.0042724609375
at 2.1338462829589844e-05
▁Sh 8.6328125
ows 0.048858642578125
▁Promise 1.95703125
, 5.51171875
▁But 2.50390625
▁F 3.958984375
aces 2.013671875
▁H 3.3984375
urd 0.029541015625
les 0.04144287109375
▁to 3.2734375
▁Be 4.99609375
come 1.1123046875
▁a 1.0439453125
▁Block 1.5634765625
b 0.0015316009521484375
uster 0.0009632110595703125
<0x0A> 0.3212890625
B 3.4375
rit 0.095458984375
ish 0.009063720703125
▁Bi 0.037109375
ote 0.00041961669921875
ch 0.009765625
▁pl 0.370361328125
c 0.00017940998077392578
▁announced 4.44921875
▁prom 3.33984375
ising 0.0010251998901367188
▁results 0.70458984375
▁for 1.5986328125
▁its 0.378173828125
▁cancer 1.1552734375
▁drug 0.10272216796875
, 2.28515625
▁Mar 0.173095703125
im 0.003139495849609375
ast 0.00022113323211669922
at 7.998943328857422e-05
, 0.427001953125
▁which 2.373046875
▁targets 4.5078125
▁the 1.396484375
▁fast 10.34375
- 0.61328125
g 0.033111572265625
row 0.0006008148193359375
ing 0.007537841796875
▁matrix 7.5859375
▁metal 0.032379150390625
lo 0.00262451171875
prote 0.0253448486328125
in 0.07293701171875
ase 0.236328125
▁( 0.9970703125
M 0.014984130859375
MP 0.00046753883361816406
) 0.2237548828125
▁market 3.66015625
. 0.3232421875
▁The 1.7568359375
▁drug 1.337890625
▁is 1.427734375
▁designed 2.99609375
▁to 0.05731201171875
▁in 1.9091796875
hib 0.002407073974609375
it 0.0008511543273925781
▁the 1.060546875
▁activity 1.8984375
▁of 0.01250457763671875
▁specific 4.75390625
▁M 0.498291015625
MP 0.0006222724914550781
s 0.47802734375
▁that 1.9638671875
▁promote 3.400390625
▁the 1.70703125
▁growth 0.744140625
▁and 1.4443359375
▁spread 0.61474609375
▁of 0.01788330078125
▁cancer 0.611328125
▁cells 0.9169921875
. 0.418212890625
▁The 2.0859375
▁drug 1.7841796875
▁is 1.28515625
▁currently 0.86328125
▁in 0.68359375
▁Ph 0.473876953125
ase 0.00205230712890625
▁III 0.50927734375
▁clin 0.86181640625
ical 0.0007066726684570312
▁tri 0.052825927734375
als 0.00014328956604003906
, 1.7919921875
▁and 0.5302734375
▁results 3.462890625
▁from 0.61572265625
▁a 2.125
▁recent 2.673828125
▁trial 1.48828125
▁demonstrate 4.3984375
▁the 2.30078125
▁drug 0.5595703125
' 0.218994140625
s 0.0002180337905883789
▁potential 1.1845703125
▁as 1.580078125
▁a 0.277587890625
▁th 3.673828125
era 0.0007114410400390625
pe 0.00019431114196777344
ut 0.00024211406707763672
ic 0.0004987716674804688
▁option 2.2421875
▁for 0.2125244140625
▁cancer 2.556640625
▁patients 0.08880615234375
. 0.12451171875
<0x0A> 0.63427734375
Mar 1.748046875
im 0.002796173095703125
ast 0.00036978721618652344
at 0.00028896331787109375
▁has 2.01171875
▁been 1.224609375
▁proven 4.625
▁to 0.35400390625
▁be 0.3505859375
▁effective 0.701171875
▁against 2.67578125
▁a 1.0732421875
▁wide 1.400390625
▁range 0.10845947265625
▁of 0.0005068778991699219
▁can 0.56298828125
cers 0.00012755393981933594
, 0.1334228515625
▁including 0.242919921875
▁pan 4.1328125
cre 0.00013899803161621094
atic 0.0245819091796875
▁cancer 1.802734375
, 0.1204833984375
▁col 1.6513671875
ore 0.0014505386352539062
ct 0.0002503395080566406
al 0.0002617835998535156
▁cancer 0.00921630859375
, 0.0238037109375
▁and 0.6953125
▁met 4.15625
ast 0.002498626708984375
atic 0.0154266357421875
▁mel 2.05078125
an 0.0001538991928100586
oma 0.004119873046875
. 0.125244140625
▁The 0.8125
▁drug 0.162109375
▁in 4.38671875
hib 0.001918792724609375
its 0.002559661865234375
▁the 0.267333984375
▁activity 0.6611328125
▁of 0.0005078315734863281
▁M 0.44775390625
MP 0.00104522705078125
s 0.498779296875
, 0.336181640625
▁which 0.11590576171875
▁play 2.283203125
▁critical 7.70703125
▁roles 0.00472259521484375
▁in 0.0007290840148925781
▁many 5.07421875
▁phys 3.125
i 0.0020427703857421875
ological 0.017913818359375
▁processes 0.263427734375
, 0.46923828125
▁such 1.84375
▁as 0.00012576580047607422
▁t 1.677734375
issue 0.0002434253692626953
▁rem 0.45263671875
od 0.002025604248046875
eling 0.07000732421875
, 0.76318359375
▁w 1.115234375
ound 6.532669067382812e-05
▁he 0.0736083984375
aling 9.417533874511719e-06
, 0.0155029296875
▁and 0.063720703125
▁tum 2.240234375
or 0.01983642578125
▁invasion 0.93798828125
. 0.638671875
▁When 3.501953125
▁M 0.69384765625
MP 0.00030541419982910156
s 0.154296875
▁are 0.2371826171875
▁over 0.481201171875
activ 2.392578125
ated 0.0010690689086914062
, 0.1595458984375
▁as 3.908203125
▁in 1.1640625
▁cancer 1.2275390625
, 1.2822265625
▁they 0.10870361328125
▁promote 1.7138671875
▁the 0.51904296875
▁growth 0.131103515625
▁and 0.08367919921875
▁spread 0.06439208984375
▁of 0.0008144378662109375
▁cancer 0.2177734375
▁cells 0.014404296875
▁by 3.05078125
▁de 0.65673828125
grad 0.001346588134765625
ing 0.00032591819763183594
▁the 0.2900390625
▁ext 0.1683349609375
rac 5.245208740234375e-06
ell 3.2782554626464844e-05
ular 0.0006456375122070312
▁matrix 0.0016984939575195312
▁( 1.9345703125
EC 0.005458831787109375
M 6.115436553955078e-05
) 1.6962890625
▁surrounding 3.1640625
▁the 1.1259765625
▁tum 0.96533203125
or 0.10113525390625
. 0.440673828125
<0x0A> 1.05078125
The 0.962890625
▁Ph 1.7763671875
ase 0.0004456043243408203
▁III 0.02667236328125
▁clin 1.2744140625
ical 8.189678192138672e-05
▁trial 0.59765625
▁conducted 3.8515625
▁by 0.15478515625
▁British 0.10076904296875
▁Bi 0.0029144287109375
ote 7.677078247070312e-05
ch 0.0016984939575195312
▁pl 1.5791015625
c 3.5643577575683594e-05
▁demonstrated 2.19921875
▁that 0.69091796875
▁Mar 0.14013671875
im 0.0008244514465332031
ast 9.620189666748047e-05
at 8.928775787353516e-05
▁can 3.14453125
▁significantly 1.064453125
▁improve 1.283203125
▁the 0.9755859375
▁pro 1.83203125
gression 0.252685546875
- 0.0120849609375
free 0.00030493736267089844
▁surv 0.0184326171875
ival 8.07046890258789e-05
▁rate 2.0703125
▁of 0.61083984375
▁patients 0.546875
▁with 0.060638427734375
▁advanced 1.193359375
▁pan 0.8642578125
cre 0.00010669231414794922
atic 0.001979827880859375
▁cancer 0.0179901123046875
. 0.387451171875
▁In 2.130859375
▁the 0.45751953125
▁trial 0.23193359375
, 0.003650665283203125
▁patients 1.171875
▁who 1.1357421875
▁received 0.052459716796875
▁Mar 0.1075439453125
im 0.0004315376281738281
ast 0.0001544952392578125
at 8.893013000488281e-05
▁had 0.86376953125
▁a 0.10430908203125
▁median 1.2109375
▁pro 0.056396484375
gression 2.7179718017578125e-05
- 0.0029659271240234375
free 0.00035572052001953125
▁surv 0.0005140304565429688
ival 1.8835067749023438e-05
▁rate 1.451171875
▁of 0.0072174072265625
▁ 0.048614501953125
2 2.216796875
. 0.70947265625
3 2.595703125
▁months 0.0452880859375
, 0.225830078125
▁compared 0.288330078125
▁to 0.058349609375
▁ 0.354248046875
1 0.15576171875
. 0.00925445556640625
6 1.9365234375
▁months 0.003719329833984375
▁for 0.64404296875
▁patients 0.57470703125
▁who 0.150390625
▁received 0.0333251953125
▁the 1.345703125
▁place 0.705078125
bo 6.306171417236328e-05
. 0.0213775634765625
▁The 1.1005859375
▁drug 1.31640625
▁showed 4.42578125
▁similar 2.244140625
▁prom 3.716796875
ising 0.00022995471954345703
▁results 0.025421142578125
▁in 0.10968017578125
▁the 2.69921875
▁treatment 0.474609375
▁of 0.000576019287109375
▁other 2.703125
▁can 0.62451171875
cers 3.6835670471191406e-05
▁as 2.75390625
▁well 0.001251220703125
. 0.482666015625
<0x0A> 0.10821533203125
However 1.4853515625
, 9.763240814208984e-05
▁despite 1.3427734375
▁Mar 4.40625
im 0.0007076263427734375
ast 5.0187110900878906e-05
at 0.00033974647521972656
' 0.0107421875
s 0.0005006790161132812
▁potential 0.86474609375
▁to 1.9501953125
▁become 0.6357421875
▁a 0.0174713134765625
▁block 0.2081298828125
b 4.875659942626953e-05
uster 6.508827209472656e-05
▁drug 0.287841796875
, 0.13916015625
▁there 1.3603515625
▁are 0.00849151611328125
▁significant 2.62890625
▁hur 0.80615234375
d 1.6689300537109375e-06
les 2.2172927856445312e-05
▁that 0.50390625
▁British 0.63916015625
▁Bi 0.0011167526245117188
ote 7.3909759521484375e-06
ch 0.00022292137145996094
▁pl 0.02557373046875
c 1.3947486877441406e-05
▁will 0.853515625
▁have 1.3212890625
▁to 1.52587890625e-05
▁overcome 0.026824951171875
. 1.2587890625
▁First 2.02734375
ly 0.830078125
, 8.916854858398438e-05
▁the 0.26953125
▁drug 0.82421875
' 1.6240234375
s 3.993511199951172e-05
▁pat 1.5732421875
ent 0.07952880859375
▁protection 0.98046875
▁has 3.72265625
▁exp 0.4921875
ired 5.1021575927734375e-05
, 0.343994140625
▁which 0.90673828125
▁means 0.497314453125
▁that 0.15771484375
▁the 3.1953125
▁drug 1.8447265625
▁is 1.544921875
▁now 1.015625
▁available 0.58251953125
▁as 0.76513671875
▁a 0.019805908203125
▁generic 0.024017333984375
▁drug 1.166015625
. 0.35498046875
▁This 0.46484375
▁will 1.5244140625
▁make 0.85107421875
▁it 0.0239105224609375
▁difficult 0.301513671875
▁for 0.0802001953125
▁British 0.5322265625
▁Bi 0.0009684562683105469
ote 4.100799560546875e-05
ch 5.352497100830078e-05
▁pl 0.055419921875
c 5.91278076171875e-05
▁to 0.0009403228759765625
▁generate 2.283203125
▁significant 0.36474609375
▁re 0.7119140625
venue 2.8133392333984375e-05
▁from 0.03814697265625
▁the 0.29931640625
▁drug 0.2041015625
. 0.3193359375
<0x0A> 0.50830078125
Second 0.52392578125
ly 0.0003876686096191406
, 2.8014183044433594e-05
▁the 0.4501953125
▁company 1.884765625
▁will 0.599609375
▁need 2.0546875
▁to 0.002445220947265625
▁demonstrate 1.4306640625
▁the 0.482177734375
▁drug 0.7431640625
' 0.00061798095703125
s 4.7326087951660156e-05
▁safety 1.171875
▁and 0.01450347900390625
▁effic 0.06878662109375
acy 1.2636184692382812e-05
▁through 4.80078125
▁further 1.884765625
▁clin 0.02581787109375
ical 1.2516975402832031e-05
▁tri 0.004810333251953125
als 3.5762786865234375e-07
. 0.5146484375
▁While 2.5078125
▁the 0.1055908203125
▁results 1.451171875
▁from 1.1494140625
▁the 0.03656005859375
▁Ph 0.12371826171875
ase 1.8835067749023438e-05
▁III 0.0010232925415039062
▁clin 0.67822265625
ical 3.707408905029297e-05
▁trial 0.08538818359375
▁are 0.62548828125
▁prom 0.1962890625
ising 1.4066696166992188e-05
, 0.0004029273986816406
▁they 2.734375
▁will 2.291015625
▁need 0.1785888671875
▁to 0.0002536773681640625
▁be 0.0005979537963867188
▁rep 0.71923828125
licated 0.0002551078796386719
▁in 0.1182861328125
▁larger 0.37255859375
- 4.5
scale 0.001728057861328125
▁tri 0.853515625
als 2.384185791015625e-07
▁to 0.6826171875
▁ensure 2.931640625
▁that 0.7255859375
▁the 0.06292724609375
▁drug 0.016815185546875
▁is 0.22802734375
▁safe 0.22509765625
▁and 0.044464111328125
▁effective 0.005157470703125
▁for 0.250244140625
▁a 1.0693359375
▁wider 0.75048828125
▁range 0.51513671875
▁of 3.910064697265625e-05
▁patients 0.8740234375
. 0.02490234375
<0x0A> 0.06573486328125
Th 1.2451171875
ird 0.00022041797637939453
ly 0.0003972053527832031
, 8.26120376586914e-05
▁Mar 3.033203125
im 0.00048232078552246094
ast 7.081031799316406e-05
at 6.210803985595703e-05
▁faces 1.7578125
▁competition 0.86328125
▁from 0.004817962646484375
▁other 0.033233642578125
▁M 0.52880859375
MP 0.0001881122589111328
▁in 0.051361083984375
hib 3.4570693969726562e-06
itors 0.01102447509765625
▁currently 3.744140625
▁in 0.353759765625
▁development 0.310302734375
. 0.263916015625
▁Several 2.892578125
▁other 1.24609375
▁ph 2.181640625
arma 8.571147918701172e-05
ce 0.00247955322265625
ut 1.430511474609375e-06
ical 2.7418136596679688e-06
▁companies 0.0015172958374023438
▁are 0.68603515625
▁developing 0.58544921875
▁M 0.460693359375
MP 9.059906005859375e-05
▁in 0.004947662353515625
hib 1.9073486328125e-06
itors 0.006252288818359375
▁to 3.384765625
▁target 2.833984375
▁cancer 2.623046875
, 1.0712890625
▁such 4.265625
▁as 5.3763389587402344e-05
▁Gla 3.236328125
x 0.000843048095703125
o 0.0013484954833984375
Smith 0.0059051513671875
K 0.000576019287109375
line 0.0003750324249267578
▁pl 0.38818359375
c 5.650520324707031e-05
' 1.8115234375
s 0.00025725364685058594
▁B 4.18359375
MS 1.5869140625
- 0.055938720703125
2 0.80322265625
7 0.08740234375
5 0.0286102294921875
2 0.047088623046875
9 5.4717063903808594e-05
1 0.0010547637939453125
▁and 0.38671875
▁Mill 4.81640625
en 0.1949462890625
ni 0.00030994415283203125
um 0.00031280517578125
▁Ph 0.0293731689453125
arma 0.01407623291015625
ce 0.0004718303680419922
ut 0.0004019737243652344
ical 0.0006208419799804688
s 0.043548583984375
▁Inc 0.74169921875
.' 0.166015625
s 0.0005397796630859375
▁( 6.953125
now 1.912109375
▁Tak 2.13671875
eda 0.0005841255187988281
▁Ph 0.0557861328125
arma 0.0032291412353515625
ce 0.006488800048828125
ut 0.0004992485046386719
ical 0.0002913475036621094
▁Co 1.4921875
. 0.82958984375
▁Ltd 0.0171356201171875
.) 0.443603515625
▁Prin 12.2890625
om 4.0703125
ast 0.00014340877532958984
at 6.592273712158203e-05
. 0.0232086181640625
▁This 3.81640625
▁means 2.23046875
▁that 0.001705169677734375
▁British 0.26708984375
▁Bi 0.00109100341796875
ote 1.537799835205078e-05
ch 5.710124969482422e-05
▁pl 0.004199981689453125
c 3.790855407714844e-05
▁will 0.01165008544921875
▁need 0.5380859375
▁to 0.00015735626220703125
▁work 4.18359375
▁hard 0.309326171875
▁to 0.002246856689453125
▁differenti 0.13427734375
ate 2.86102294921875e-06
▁Mar 0.5712890625
im 0.0006341934204101562
ast 6.16312026977539e-05
at 5.53131103515625e-05
▁from 0.037445068359375
▁its 0.94775390625
▁compet 0.031982421875
itors 0.0014553070068359375
▁and 0.44775390625
▁position 3.794921875
▁it 0.26611328125
▁as 0.0084686279296875
▁the 0.77685546875
▁most 3.55078125
▁effective 0.1187744140625
▁M 1.099609375
MP 0.00010442733764648438
▁in 0.0010366439819335938
hib 3.4570693969726562e-06
itor 0.0003139972686767578
. 2.7265625
<0x0A> 0.00852203369140625
B 4.125
rit 0.0804443359375
ish 0.00021719932556152344
▁Bi 0.0024814605712890625
ote 0.0004343986511230469
ch 0.0004436969757080078
▁pl 0.01247406005859375
c 3.325939178466797e-05
▁will 2.3359375
▁need 1.0244140625
▁to 0.005859375
▁invest 2.705078125
▁in 3.98828125
▁market 2.66015625
ing 0.0016880035400390625
▁and 0.0374755859375
▁research 4.078125
▁and 0.293212890625
▁development 0.00020182132720947266
▁to 0.2919921875
▁ensure 0.96044921875
▁that 0.0986328125
▁Mar 0.08843994140625
im 0.0007171630859375
ast 5.7816505432128906e-05
at 6.878376007080078e-05
▁becomes 2.513671875
▁a 0.01404571533203125
▁block 0.2447509765625
b 4.589557647705078e-05
uster 3.3736228942871094e-05
▁drug 0.01605224609375
. 0.049652099609375
▁The 0.27587890625
▁company 0.031585693359375
▁will 0.2105712890625
▁need 0.77978515625
▁to 0.0006012916564941406
▁conduct 2.259765625
▁further 1.212890625
▁tri 4.25
als 2.9802322387695312e-06
▁to 0.19384765625
▁demonstrate 0.2176513671875
▁the 0.019256591796875
▁drug 0.024383544921875
' 0.0003628730773925781
s 2.181529998779297e-05
▁safety 0.323974609375
▁and 0.00429534912109375
▁effic 0.00457000732421875
acy 9.179115295410156e-06
▁and 1.40234375
▁to 1.5712890625
▁determine 3.65625
▁the 0.91064453125
▁optimal 0.439697265625
▁do 1.7060546875
se 4.172325134277344e-06
▁and 0.338134765625
▁treatment 1.8017578125
▁for 8.3984375
▁each 3.03515625
▁cancer 1.021484375
▁type 0.085693359375
. 0.00457000732421875
▁Additionally 1.9853515625
, 5.1021575927734375e-05
▁the 0.2496337890625
▁company 0.007556915283203125
▁will 0.0171661376953125
▁need 0.0059967041015625
▁to 0.0002301931381225586
▁develop 1.6240234375
▁strong 5.5234375
▁partners 1.2060546875
hips 0.0010356903076171875
▁with 0.03515625
▁phys 4.82421875
icians 0.0054931640625
, 1.1357421875
▁hosp 1.23046875
it 5.602836608886719e-06
als 2.384185791015625e-07
, 0.003749847412109375
▁and 0.0050048828125
▁other 1.220703125
▁st 1.7490234375
ake 5.960464477539062e-07
hold 9.953975677490234e-05
ers 1.1920928955078125e-07
▁to 0.130859375
▁ensure 0.49560546875
▁that 0.0299072265625
▁Mar 0.6357421875
im 0.00101470947265625
ast 4.100799560546875e-05
at 6.23464584350586e-05
▁is 0.1607666015625
▁widely 0.4130859375
▁pres 3.1875
cribed 0.0001837015151977539
▁and 0.31201171875
▁used 0.326416015625
▁in 2.376953125
▁the 1.0400390625
▁treatment 0.2188720703125
▁of 0.0002739429473876953
▁cancer 0.0199127197265625
. 0.07861328125
<0x0A> 0.0255584716796875
Des 2.29296875
p 6.639957427978516e-05
ite 3.147125244140625e-05
▁the 0.76611328125
▁challeng 0.243896484375
es 0.0001266002655029297
, 0.626953125
▁Mar 1.5556640625
im 0.0005512237548828125
ast 3.1948089599609375e-05
at 2.4437904357910156e-05
' 2.72265625
s 2.7298927307128906e-05
▁potential 0.115966796875
▁to 0.75244140625
▁become 0.048126220703125
▁a 0.0013151168823242188
▁block 0.0184478759765625
b 2.8848648071289062e-05
uster 1.4543533325195312e-05
▁drug 0.01727294921875
▁is 0.32470703125
▁significant 0.328369140625
. 0.046966552734375
▁The 0.38671875
▁drug 0.045928955078125
▁has 0.96337890625
▁demonstrated 1.546875
▁prom 0.37841796875
ising 1.6927719116210938e-05
▁results 0.0168914794921875
▁in 0.01467132568359375
▁Ph 2.876953125
ase 3.2782554626464844e-05
▁III 0.0131072998046875
▁clin 0.04327392578125
ical 5.4836273193359375e-06
▁tri 0.00040149688720703125
als 1.1920928955078125e-07
▁and 1.1064453125
▁has 0.314697265625
▁the 0.5224609375
▁potential 0.0193023681640625
▁to 9.822845458984375e-05
▁become 1.9228515625
▁a 0.1962890625
▁valuable 3.31640625
▁th 0.6845703125
era 1.430511474609375e-06
pe 4.887580871582031e-06
ut 3.4809112548828125e-05
ic 6.079673767089844e-06
▁option 0.0023193359375
▁for 0.01114654541015625
▁cancer 0.1412353515625
▁patients 0.00037860870361328125
. 0.0567626953125
▁British 0.89892578125
▁Bi 0.0006322860717773438
ote 1.823902130126953e-05
ch 9.775161743164062e-05
▁pl 0.000621795654296875
c 2.1576881408691406e-05
▁must 5.33984375
▁work 1.2294921875
▁hard 0.1280517578125
▁to 0.002292633056640625
▁overcome 0.6044921875
▁the 0.042694091796875
▁hur 0.63232421875
d 3.337860107421875e-06
les 4.1961669921875e-05
▁and 0.70654296875
▁position 0.83203125
▁Mar 0.14208984375
im 0.00044155120849609375
ast 1.0609626770019531e-05
at 8.094310760498047e-05
▁as 0.0020751953125
▁the 0.0772705078125
▁most 1.26953125
▁effective 0.0022602081298828125
▁M 0.036224365234375
MP 0.0001266002655029297
▁in 0.0006098747253417969
hib 2.9802322387695312e-06
itor 7.82012939453125e-05
▁on 0.86328125
▁the 4.279613494873047e-05
▁market 0.00011789798736572266
. 0.017059326171875
▁With 1.16796875
▁the 0.6064453125
▁right 0.05230712890625
▁invest 0.65478515625
ment 0.376953125
▁and 0.5048828125
▁strategy 2.205078125
, 0.0211181640625
▁Mar 0.2061767578125
im 0.0005507469177246094
ast 3.886222839355469e-05
at 4.696846008300781e-05
▁could 1.1103515625
▁become 0.100341796875
▁a 0.062408447265625
▁key 4.5546875
▁player 0.2529296875
▁in 0.00021898746490478516
▁the 0.0040435791015625
▁fight 0.87255859375
▁against 6.103515625e-05
▁cancer 0.0004935264587402344
. 0.21728515625
